Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Capitalization 96.69B 145B P/E ratio 2025 *
30.9x
P/E ratio 2026 * 26.5x
Enterprise value 106B 159B EV / Sales 2025 *
6.72x
EV / Sales 2026 * 6.18x
Free-Float
99.87%
Yield 2025 *
1.5%
Yield 2026 * 1.69%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.76%
1 week-1.09%
Current month-1.46%
1 month-2.02%
3 months+5.72%
6 months+7.64%
Current year+5.59%
More quotes
1 week
298.10
Extreme 298.1
305.00
1 month
291.47
Extreme 291.465
311.38
Current year
265.14
Extreme 265.14
313.55
1 year
228.65
Extreme 228.65
313.55
3 years
228.65
Extreme 228.65
319.78
5 years
227.26
Extreme 227.26
342.75
10 years
71.04
Extreme 71.04
342.75
More quotes
Director TitleAgeSince
Chief Executive Officer 58 19-05-31
Director of Finance/CFO 59 20-09-30
Chief Tech/Sci/R&D Officer 62 20-09-30
Manager TitleAgeSince
Director/Board Member 70 97-03-31
Director/Board Member 68 13-08-13
Director/Board Member 66 16-02-15
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+0.76%-1.09%+12.70%+0.03%96.69B
0.00%0.00%+33.29%+5.70%51.13B
+1.50%-0.85%+97.29%+75.66%34.1B
-0.77%-2.68%-23.06%-33.61%29.03B
+0.30%-7.54%-6.50%+5.27%16.05B
-1.15%-3.11%+40.30%-28.11%12.07B
+1.16%-5.43%+592.83%+349.45%12.04B
+1.63%-5.18%-2.69%-14.35%11.99B
+3.83%+1.20%+47.28%+31.85%10.55B
+0.96%-0.71%+10.05%-34.35%8.72B
Average +0.82%-2.77%+80.15%+35.75% 28.24B
Weighted average by Cap. +0.62%-1.97%+48.35%+20.24%
See all sector performances
2025 *2026 *
Net sales 15.78B 23.68B 16.91B 25.37B
Net income 3.11B 4.67B 3.63B 5.45B
Net Debt 9.39B 14.08B 7.89B 11.84B
More financial data * Estimated data
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Employees
32,698
Calendar
Related indices
More about the company
Date Price Change Volume
24-09-10 301.51 $ +0.37% 685,465
24-09-09 300.41 $ -1.18% 571,485
24-09-06 303.99 $ +0.29% 515,094
24-09-05 303.10 $ -0.29% 743,421
24-09-04 303.99 $ -0.67% 537,848

Delayed Quote Australian S.E., September 10, 2024 at 01:59 am EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
199.74USD
Average target price
210.14USD
Spread / Average Target
+5.21%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW